Eli Lilly stock gets bump after results for its mid-stage diabetes drug trial shows positive results (LLY)

• On Thursday, pharma giant Eli Lilly and Co. announced positive results in a mid-stage trial for its experimental new diabetes drug. The company’s stock rose 3% on the news. 
• The drug significantly reduced blood sugar levels and promoted weight loss in patients with type 2 diabetes. 
• The late-stage trial for this drug is expected to be completed in 2021. 
• This drug has to potential to boost Lilly’s growing portfolio of drugs extending across the areas of oncology, cardiovascular, diabetes, critical care, neuroscience, men’s health and musculoskeletal fields.

Join the conversation about this story »

NOW WATCH: Beware one huge mistake investors often make when the economy is at a crossroads, says Charles Schwab’s investment chief